SCHEMBL147322

SCHEMBL147322

[c]1ccc(-n2cncn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
KDM4E B2RXH2 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP2A6 P11509 1/20 0.50
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
FBP1 P09467 1/20 0.44
HSP90AA1 P07900 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
MAPK10 P53779 1/20 0.36
RAB9A P51151 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
DPP4 P27487 2/20 0.33
CYP11B2 P19099 1/20 0.33
SMYD3 Q9H7B4 1/20 0.33
BRS3 P32247 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27905069 0.84 SMN1; SMN2 (0.72) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL10508046 0.77 SMN1; SMN2 (0.59) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL28108762 0.77 KDM4E (0.64) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL2342212 0.76 CYP2A6 (0.53) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL10468454 0.76 CYP2A6 (0.53) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL28006297 0.76 CYP2A6 (0.62) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL676377 0.74 SMN1; SMN2 (0.60) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL4573337 0.74 SMN1; SMN2 (0.60) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL5663652 0.74 KDM4E (0.60) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2
SCHEMBL118713 0.74 KDM4E (0.60) SMN1; SMN2KDM4EALDH1A1CYP2A6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME RAPPTA THERAPEUTICS OY (FI) 2024-05-30 US claimed
EP-4288412-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME Rappta Therapeutics Oy (FI) 2023-12-13 EP claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
CN-114560867-B Oxygen bridge bicycloheptene sulfonate compound containing five-membered nitrogen heterocycle and application thereof in preparation of breast cancer resisting drugs 武汉大学 2023-06-06 CN claimed
US-20220389009-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 GFB (ABC), LLC 2022-12-08 US claimed
CN-114761000-A Substituted 1, 6-naphthyridine inhibitors of CDK5 金翅雀生物公司 2022-07-15 CN claimed
CN-114560867-A Oxocycloheptene sulfonate compound containing five-membered nitrogen heterocycle and application thereof in preparation of anti-breast cancer drugs 武汉大学 2022-05-31 CN claimed
WO-2022011274-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 GOLDFINCH BIO, INC. (US) 2022-01-13 WO claimed
WO-2021067569-A1 SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 GOLDFINCH BIO, INC. (US) 2021-04-08 WO claimed
EP-3071205-B1 BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS FORMA THERAPEUTICS INC (US) 2020-02-05 EP claimed
EP-1458393-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-09-22 EP claimed
US-20030158186-A1 Compositions and methods for treating heart failure CYTOKINETICS, INCORPORATED 2003-08-21 US claimed
WO-2003059265-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS, INC. (US) 2003-07-24 WO claimed
WO-2003053443-A1 SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2003-07-03 WO claimed
US-5026848-A Antirhinovirus agents SYNPHAR LABORATORIES INCORPORATED (CA) 1991-06-25 US claimed
EP-0335636-A1 Antiviral compounds SYNPHAR LABORATORIES INC. (CA) 1989-10-04 EP claimed
EP-0023026-B1 MIXTURES OF OPTICAL BRIGHTENERS AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1984-02-22 EP claimed
EP-0023028-B1 MIXTURES OF OPTICAL BRIGHTENERS AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1982-12-15 EP claimed
US-4336155-A CYANOSTYRYL COMPOUNDS AND OTHER BRIGHTENER HOECHST AKTIENGESELLSCHAFT (DE) 1982-06-22 US claimed
US-4330427-A Mixtures of optical brighteners HOECHST AKTIENGESELLSCHAFT (DE) 1982-05-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 SMN1; SMN2 2039/4885KDM4E 4330/4885ALDH1A1 1318/4885
US-20220389009-A1 SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 CDK5, CDK5R1, PKD1 SMN1; SMN2 2901/4885KDM4E 2661/4885ALDH1A1 2375/4885
US-20240174603-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME PPM1A, PPP2CA, PPP3CA SMN1; SMN2 2249/4885KDM4E 2199/4885ALDH1A1 1616/4885
US-20030158186-A1 Compositions and methods for treating heart failure MYH2, TNNI3, MYLK2 SMN1; SMN2 633/4885KDM4E 2094/4885ALDH1A1 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.